Scribd Logo
Upload

Welcome to Scribd!

  • 62 views

    BRCA1 Associated Epigenetic Regulation of p73 Mediates Effector Pathway For Chemosensitivity in Ovarian Carcinoma

    Uploaded by

    Dr.Yogender Singh
    This study found that the p73 tumor suppressor gene plays an important role in mediating chemosensitivity to cisplatin in BRCA1-deficient ovarian carcinoma. The researchers discovered that cisplatin treatment selectively upregulates the TAp73 isoform in BRCA1-deficient murine and human ovarian cancer cell lines. Knockdown of TAp73 abolished cisplatin-induced cell death and chemosensitivity in these cell lines. They also determined that the ZEB1 transcriptional repressor normally suppresses TAp73 expression in BRCA1-expressing cells by binding to TAp73, but DNA methylation of the ZEB1 locus prevents this binding in BRCA1-deficient cells, allowing

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd

    BRCA1 Associated Epigenetic Regulation of p73 Mediates Effector Pathway For Chemosensitivity in Ovarian Carcinoma

    Uploaded by

    Dr.Yogender Singh
    62 views10 pages
    This study found that the p73 tumor suppressor gene plays an important role in mediating chemosensitivity to cisplatin in BRCA1-deficient ovarian carcinoma. The researchers discovered that cisplatin treatment selectively upregulates the TAp73 isoform in BRCA1-deficient murine and human ovarian cancer cell lines. Knockdown of TAp73 abolished cisplatin-induced cell death and chemosensitivity in these cell lines. They also determined that the ZEB1 transcriptional repressor normally suppresses TAp73 expression in BRCA1-expressing cells by binding to TAp73, but DNA methylation of the ZEB1 locus prevents this binding in BRCA1-deficient cells, allowing

    Original Title

    Presentation 11 Copy.pptxibrahim Et All

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This study found that the p73 tumor suppressor gene plays an important role in mediating chemosensitivity to cisplatin in BRCA1-deficient ovarian carcinoma. The researchers discovered that cisplatin treatment selectively upregulates the TAp73 isoform in BRCA1-deficient murine and human ovarian cancer cell lines. Knockdown of TAp73 abolished cisplatin-induced cell death and chemosensitivity in these cell lines. They also determined that the ZEB1 transcriptional repressor normally suppresses TAp73 expression in BRCA1-expressing cells by binding to TAp73, but DNA methylation of the ZEB1 locus prevents this binding in BRCA1-deficient cells, allowing

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    62 views10 pages

    BRCA1 Associated Epigenetic Regulation of p73 Mediates Effector Pathway For Chemosensitivity in Ovarian Carcinoma

    Uploaded by

    Dr.Yogender Singh
    This study found that the p73 tumor suppressor gene plays an important role in mediating chemosensitivity to cisplatin in BRCA1-deficient ovarian carcinoma. The researchers discovered that cisplatin treatment selectively upregulates the TAp73 isoform in BRCA1-deficient murine and human ovarian cancer cell lines. Knockdown of TAp73 abolished cisplatin-induced cell death and chemosensitivity in these cell lines. They also determined that the ZEB1 transcriptional repressor normally suppresses TAp73 expression in BRCA1-expressing cells by binding to TAp73, but DNA methylation of the ZEB1 locus prevents this binding in BRCA1-deficient cells, allowing

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Download as pptx, pdf, or txt
    of 10

    BRCA1 Associated epigenetic

    regulation of p73 mediates


    effector pathway for
    chemosensitivity in ovarian
    carcinoma
    INTRODUCTION
     Ovarian carcinoma is the fifth commonest carcinoma in the world.
     Commonest gynecological cancer in united kingdom.
     It arises due to germ line mutation of the BRCA1 tumor suppressor
    gene.

     Mutation in BRCA1 result in loss of p53 activity.


     despite the loss of p53 BRAC1 cell exhibit increased sensitivity in
    platinum based chemotherapy.

     As well as improved overall survival.


     Effector pathway behind this concept is poorly understood.

    According to the multiple studies on BRCA1 deficient human
    and murine carcinoma , Ibrahim etall shows that selective up
    regulation of trans activating isoform of p53 related gene P73
    (TAP73) is involve in this phenomenon.

    TAP73 serves as an important contributor to the platinum


    induced DNA damage response and to chemosensitivity in
    ovarian carcinoma.


    TAP73 does not play any role in BRCA1 expressing cells but
    knock down of TAP73 can abolish the effect of cisplatin.
    MATERIAL AND METHODS
    Tissue culture and reagents for study of murine model
    Murine ovarian carcinoma cell lines (T1,T2,T3,TBR2,TBR5 and
    TBR6).
    Western blot analysis to confirm the absence of whole length
    BRCA1 protein.
    These lines were maintained in 10% fetal bovine serum ,100
    IU/ML Penicillin and 100 microgram /ml of streptomycin.
    For study of human cells
    UWB 1.289 human cell lines.
    1:1 RPMI 1640/MEGM supplemented with 3% fetal bovine serum.
    RNA analysis ,lentiviral/retroviral production
    And chromatin immunoprecipitation
     QRT-PCR analysis
     Cotransfection is used to generate lentiviral and retroviral stock.
    Bisulphite treatment and methylation analysis
     200 to 500ng of genomic DNA were used.
     After confirmation of desired product methylation was quantitated in
    sequence product by measuring the heights of the C and T peaks.
    Patient sample acquisition and processing
     Tumor specimens were obtained from from the MGH gynecological
    tissue repository.
     RNA/DNA was isolated from dry frozen tumor samples.
    RESULTS
    Cisplatin sensitivity of BRCA1 deficient ovarian
    carcinoma cells
     BRCA1 associated tumor lines consistently exhibited significantly
    increased sensitivity to cisplatin comparison to wild type in murine
    model.
     In human assay showed the same result confirming the increase
    platinum sensitivity of UWB 1.289 cells relative to their isogenic
    BRCA1 counter part.
     Ibrahim et all found that cisplatin induces apoptotic death in both
    murine and human BRCA1 deficient cells ,as evidence by cleavage of
    poly (ADP ribose) polymerase on western blot analysis.
    Expression of P73 and its target genes correlate with
    cisplatin sensitivity in BRCA1 deficient cells
     After cisplatin induction Ibrahim etall observed robust induction of
    the P53 regulated proapoptotic genes Noxa ,Puma and P53AIP1 in
    both human and murine BRCA1 deficient cells but not in wild type.
     These finding suggest a distinct cell death pathway in the absence of
    BRCA1 which involve P53 family member P73.
    TAP73 is necessary for cisplatin sensitivity
     TAP73 knock down essentially abolished cisplatin induced Noxa
    expression in the three murine BRCA1 deficient ovarian carcinoma
    cells.
     Knock down of TAP73 induced significant resistant in human BRCA1
    deficient UWB 1.289 cells although it did not affect proliferation and
    cell viability in the absence of cisplatin.
    The ZEB1 transcriptional repressor of TAP73 in BRCA1
    expressing cells
     Ibrahim et all observed that binding of ZEB1 with TAP73 potently
    repressed TAP73 mRNA expression.
     This is the main reason that why the phenomenon of TAP73 exist only
    in BRCA1 deficient ovarian carcinoma.

    Methylation of ZEB1 locus controls the binding of ZEB1


    with TAP73
     To confirm this model Ibrahim et all treated ZEB1 with 5 azacytidine
    (demethylating agent) which result in 100 fold increase in ZEB1
    binding in BRCA1 deficient cells.
     It shows that methylation of ZEB1 locus will decrease the binding of
    ZEB1 and TAP73 and increase the expression of TAP73 which
    ultimately increase the chemosensitivity for cisplatin.
    DISCUSSION
     TAP73 is an important contributor to chemosensitivity in
    BRCA1 deficient carcinoma tumor.

     Ablation of TAP73 promotes chemoresistance.


     The description of pathway responsible for cell death was
    good but not proper.

     actual concept behind this phenomenon is not present in this


    research paper.

     Research is still going on to find the actual concept

    You might also like